Product Description
Choline alfoscerate is a member of the class of phosphocholines that is the choline ester of sn-glycero-3-phosphate. It is one of the major osmolyte in the renal medullary cells (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Choline-Alfoscerate)
Mechanisms of Action: GM2 Activator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Greece | Italy | Korea | Pakistan | Philippines | Poland | Russia | Ukraine | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: AZIENDA OSPEDALIERA CARDARELLI
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Alzheimer Disease|Cognitive Dysfunction|Stroke|Dementia|Depressive Disorder
Phase 3: Type 2 Diabetes
Phase 2: Cognitive Dysfunction|Alzheimer Disease
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05257902 |
CHOLDEPS | N/A |
Unknown status |
Depressive Disorder, Major |
2023-03-01 |
2024-12-03 |
Primary Endpoints|Treatments|Trial Status |
|
ACTRN12620001278921p |
2006-7041-83/hah | N/A |
Not yet recruiting |
Type 2 Diabetes|Heart Failure |
2021-04-01 |
|||
NCT03228498 |
CONIVAD | P2 |
Completed |
Cognitive Dysfunction |
2019-07-09 |
2020-01-14 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
2009-016955-23 |
ASCOTALCO | P2 |
Terminated |
Alzheimer Disease |
2012-09-01 |
2025-07-01 |
Treatments |
|
2008-005969-55 |
ND | P2 |
Active, not recruiting |
Alzheimer Disease |
2011-05-12 |
2022-03-12 |
Treatments |
|
NCT03249259 |
B-1508-312-006 | P3 |
Completed |
Type 2 Diabetes |
2019-06-30 |
2019-10-09 |
Patient Enrollment|Primary Completion Date|Study Completion Date |
|
2011-006304-13 |
2011-006304-13 | P3 |
Active, not recruiting |
Unknown |
2016-05-14 |
2022-03-13 |
Treatments |
|
2025-520685-21-00 |
2025-520685-21-00 | P4 |
Not yet recruiting |
Cognitive Dysfunction |
2025-06-30 |
2025-05-02 |
Treatments |
|
NCT05383183 |
COALA | P4 |
Recruiting |
Alzheimer Disease |
2025-06-30 |
2024-03-22 |
Primary Endpoints|Start Date|Treatments |
|
2025-520899-25-00 |
CARTESIO | P4 |
Recruiting |
Depressive Disorder |
2025-06-30 |
2025-05-02 |
Treatments |
|
NCT05041790 |
ESCALADE | P4 |
Unknown status |
Cognitive Dysfunction |
2024-11-30 |
2024-12-03 |
Primary Endpoints|Treatments|Trial Status |
|
NCT05050604 |
INFINITE-V (B78_03VCI2004) | P4 |
Unknown status |
Cognitive Dysfunction |
2024-11-01 |
2024-11-05 |
||
NCT02648906 |
DWB_GTM001 | P4 |
Unknown status |
Alzheimer Disease |
2018-11-01 |
2019-03-20 |
Treatments |
|
NCT01363648 |
GLITTER | P4 |
Completed |
Dementia|Cognitive Dysfunction|Stroke |
2013-03-01 |
2019-03-19 |
Treatments |